Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
Press Releases
Keymed Biosciences Inc.  
February 8, 2025

Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis

CHENGDU, China, Feb. 7, 2025 /PRNewswire/ -- KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application

logo salamanca press

Salamanca Press

Local & Social